[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100287556":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":47,"collaborators":49,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PMMTB",null,"This study of the PMMTB will include all patients \\>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.\n\nAll standard of care functions will be performed by standard procedures.",[13],"Other: PMMTB (Precision Medicine Molecular Tumor Board)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"PMMTB (Precision Medicine Molecular Tumor Board)","PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.",[9],[20],{"name":21,"affiliation":5,"role":22},"Dustin Deming, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Cancer Connect","CONTACT","8006228922","clinicaltrials@cancer.wisc.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"University of Wisconsin Carbone Cancer Center","RECRUITING","Madison","Wisconsin","53792","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-89.40123,43.07305,{"lat":42,"lon":41},[45],{"name":25,"role":26,"phone":46,"phoneExt":10,"email":28},"800-622-8922",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[50],{"name":51,"class":52},"National Cancer Institute (NCI)","NIH","100287556",false,"NCT03023202","UWCCC Molecular Tumor Board Registry","UWCCC Precision Medicine Molecular Tumor Board Registry","Inclusion Criteria:\n\n* Clinically suspected or histologically confirmed solid or hematological malignancy\n* Undergoing genetic testing of tumor\n* Ability to understand written informed consent document\n* Willingness to sign written informed consent document\n\nExclusion Criteria:\n\n* Pediatric patients (age\\\u003C18 years) will be excluded due to a lack of expertise on the molecular tumor committee","ALL","18 Years",{"count":62,"type":63},10000,"ESTIMATED","OBSERVATIONAL","This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.",[67,68],"Hematologic Neoplasms","Solid Neoplasm","2026-04-07",{"date":71,"type":72},"2026-04-13","ACTUAL",{"date":74,"type":72},"2016-03-30",{"date":76,"type":63},"2029-03",{"name":5,"class":6},1]